The investigations target a series of high-profile acquisitions. Arcosa, Inc. (ACA) is currently slated for sale to CRH Americas, Inc. at $150.00 per share, while Apogee Therapeutics, Inc. (APGE) faces a buyout by AbbVie Inc. at $135.11 per share. Additionally, the firm is reviewing the merger between Boundless Bio, Inc. (BOLD) and Serapha Bio, Inc., which would result in current shareholders holding approximately 3.7% of the combined entity. Finally, Selectis Health, Inc. (GBCS) is being examined following its agreement to be acquired by Black Pearl Equities II, LLC for $5.75 per share.
In section Releases
Monteverde & Associates Launches Investigations Into Four Corporate Mergers
Shareholders of Arcosa, Apogee Therapeutics, Boundless Bio, and Selectis Health are under scrutiny as New York-based Monteverde & Associates PC initiates investigations into their respective merger and acquisition deals. The law firm aims to determine if these transactions provide adequate value or violate fiduciary duties to public investors.
Juan Monteverde, head of the firm, emphasizes that these inquiries are part of a broader practice focused on holding corporate directors and officers accountable for transaction terms. Investors holding common stock in these companies are invited to contact the firm to discuss potential concerns regarding the fairness of these proposed deals. The firm, operating out of the Empire State Building, notes that these consultations are provided at no cost or obligation to the shareholders.
Comments (0)
No comments yet. Be the first!